Drug affinity to human serum albumin prediction by retention of cetyltrimethylammonium bromide pseudostationary phase in micellar electrokinetic chromatography and chemically advanced template search descriptors

Abstract

The development of high-throughput methods for the estimation of physicochemical and biological properties of drug candidates is highly desired in the pharmaceutical landscape. Affinity to plasma protein is one of the most important biological properties, which should be taken under concern during the design and assessment of future potential medicines. The main goal of this study was to develop a quantitative retention-activity relationship model, with rationalized in vivo and in silico approach to predict the affinity to human serum albumin (HSA), which is one of the most important plasma proteins. To achieve this goal, a set of 27 chemically diverse drugs with known affinity to HSA were analyzed by micellar electrokinetic chromatography (MEKC). The proposed model for HSA affinity assessment was based on retention in hexadecyltrimethylmonium bromide (CTAB) pseudostationary phase and chemically advanced template search (CATS) pharmacophore descriptors. The comparison of various regression methods, namely multiple linear regression (MLR), partial least squares regression (PLS), orthogonal partial least squares (OPLS), and support vector machine (SVM) were performed to develop a model with highest predictability. The obtained models are suitable for the prediction of drug affinity to human serum albumin using retention factor determined by MEKC and CATS descriptors, and only slightly differ in terms of coefficients of determination, Q2 value calculated using leave-one-out cross-validation technique and root-mean-squared error of cross-validation (RMSECV) as well as root-mean-square error in prediction (RMSEP) obtained by external validation.